CH626629A5 - - Google Patents
Download PDFInfo
- Publication number
- CH626629A5 CH626629A5 CH1280977A CH1280977A CH626629A5 CH 626629 A5 CH626629 A5 CH 626629A5 CH 1280977 A CH1280977 A CH 1280977A CH 1280977 A CH1280977 A CH 1280977A CH 626629 A5 CH626629 A5 CH 626629A5
- Authority
- CH
- Switzerland
- Prior art keywords
- product
- adjuvant
- mmol
- antigen
- isoglutamine
- Prior art date
Links
- 239000000047 product Substances 0.000 description 24
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- -1 Benzyl ester Chemical class 0.000 description 2
- AEFLONBTGZFSGQ-GSVOUGTGSA-N D-isoglutamine Chemical compound NC(=O)[C@H](N)CCC(O)=O AEFLONBTGZFSGQ-GSVOUGTGSA-N 0.000 description 2
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- NKUHWWPUOXOIIR-CRCLSJGQSA-N (4r)-5-amino-4-[[(2s)-2-azaniumylpropanoyl]amino]-5-oxopentanoate Chemical compound C[C@H](N)C(=O)N[C@@H](C(N)=O)CCC(O)=O NKUHWWPUOXOIIR-CRCLSJGQSA-N 0.000 description 1
- GAWAYYRQGQZKCR-REOHCLBHSA-N (S)-2-chloropropanoic acid Chemical compound C[C@H](Cl)C(O)=O GAWAYYRQGQZKCR-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008534 L-alanines Chemical class 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 150000008495 β-glucosides Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7631935A FR2368282A1 (fr) | 1976-10-22 | 1976-10-22 | Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH626629A5 true CH626629A5 (cs) | 1981-11-30 |
Family
ID=9179110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1280977A CH626629A5 (cs) | 1976-10-22 | 1977-10-20 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4185089A (cs) |
| JP (1) | JPS5353628A (cs) |
| CH (1) | CH626629A5 (cs) |
| DE (1) | DE2747379A1 (cs) |
| FR (1) | FR2368282A1 (cs) |
| GB (1) | GB1590659A (cs) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2428051A1 (fr) * | 1978-06-05 | 1980-01-04 | Anvar | Nouveaux composes du type muramyl-peptide et medicaments les contenant |
| US4377570A (en) * | 1979-01-29 | 1983-03-22 | Merck & Co., Inc. | Immunologically active dipeptidyl saccharides and methods of preparation |
| FR2449697A1 (fr) | 1979-02-20 | 1980-09-19 | Anvar | Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant |
| FI75578C (fi) * | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
| US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5149529A (en) * | 1988-04-08 | 1992-09-22 | Board Of Trustees Of Leland Chiron Corporation | Compositions and treatment for herpes simplex |
| US5416070A (en) * | 1988-07-08 | 1995-05-16 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US4950645A (en) * | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| RU2083588C1 (ru) * | 1995-09-11 | 1997-07-10 | Безруков Михаил Васильевич | Способ получения мурамилпептидов |
| AUPR079700A0 (en) | 2000-10-17 | 2000-11-09 | Alchemia Pty Ltd | Combinatorial libraries of monosaccharides |
| EP1670508B1 (en) | 2003-02-28 | 2012-10-24 | Trustees Of The University Of Pennsylvania | Compositions, methods and kits relating to poxvirus subunit vaccines |
| WO2006112869A2 (en) * | 2004-07-19 | 2006-10-26 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
| KR101203401B1 (ko) | 2005-06-08 | 2012-11-22 | 이쉥 바이오파마(싱가포르)피티이 리미티드 | 폴리이노신산-폴리시티딜산-기초 보조제 |
| US7868159B2 (en) * | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| EP2136832B1 (en) | 2007-03-26 | 2015-09-02 | General Regeneratives Limited | Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
| WO2009082593A2 (en) * | 2007-11-30 | 2009-07-02 | Baylor College Of Medicine | Dendritic cell vaccine compositions and uses of same |
| US9808504B2 (en) | 2009-09-22 | 2017-11-07 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
| CA2846486C (en) | 2011-07-12 | 2019-08-20 | Philadelphia Health & Education Corporation | Novel clostridium difficile dna vaccine |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| WO2016105274A1 (en) | 2014-12-23 | 2016-06-30 | Yisheng Biopharma (Singapore) Pte Ltd | A rabies composition comprising pika adjuvant |
| WO2016138286A1 (en) | 2015-02-26 | 2016-09-01 | Stc.Unm | Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
| WO2020140007A1 (en) | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| WO2025096754A1 (en) | 2023-10-31 | 2025-05-08 | Musc Foundation For Research Development | The use of enolase inhibitor pomhex for treatment of fibrosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082736A (en) * | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
| US4082735A (en) * | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
-
1976
- 1976-10-22 FR FR7631935A patent/FR2368282A1/fr active Granted
-
1977
- 1977-10-20 CH CH1280977A patent/CH626629A5/fr not_active IP Right Cessation
- 1977-10-21 GB GB43832/77A patent/GB1590659A/en not_active Expired
- 1977-10-21 JP JP12588277A patent/JPS5353628A/ja active Granted
- 1977-10-21 DE DE19772747379 patent/DE2747379A1/de not_active Ceased
- 1977-10-25 US US05/845,105 patent/US4185089A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4185089A (en) | 1980-01-22 |
| FR2368282B1 (cs) | 1980-10-17 |
| DE2747379A1 (de) | 1978-04-27 |
| JPS6126800B2 (cs) | 1986-06-21 |
| JPS5353628A (en) | 1978-05-16 |
| FR2368282A1 (fr) | 1978-05-19 |
| GB1590659A (en) | 1981-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH626629A5 (cs) | ||
| US4094971A (en) | Immunological adjuvant agents active in aqueous solution | |
| DE69017149T2 (de) | Synthetische Peptide nützlich als universale Träger für die Herstellung von immunogenischen Konjugaten und deren Benützung in der Entwicklung von synthetischen Impfstoffen. | |
| FR2596990A1 (fr) | Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien | |
| DE2450355A1 (de) | Aus n-acyl-muraminsaeurederivaten gebildete adjuvanzien und diese enthaltende impfstoffe | |
| EP0004512B1 (fr) | Composés esters de muramyl-peptide et leurs applications dans les compositions pharmaceutiques et réactifs de laboratoire | |
| EP0003833B1 (de) | Antigenderivate, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate | |
| EP0049666B1 (fr) | Nouvelles substances biologiquement actives, leur obtention à partir de caséine humaine et compositions les contenant | |
| JPH02502538A (ja) | 分子状デコイアント及びその使用方法 | |
| EP0015810A1 (fr) | N-acétyl-L-(N-méthyl-alanyl)-D-isoglutamine et compositions la contenat, pour l'utilisation en tant que régulateurs des mécanismes immunitaires | |
| EP0001945A1 (fr) | Nouveaux polysaccharides extraits de corps microbiens d'Haemophilus Influenzae, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| CH634041A5 (fr) | Derives de la pepstatine, leur preparation et composition les contenant. | |
| CH648043A5 (fr) | Dipeptides, leur preparation et les medicaments qui les contiennent. | |
| CH616943A5 (cs) | ||
| EP0006068B1 (fr) | Composés du type muramyl-peptide et médicaments les contenant | |
| DE2710455C2 (de) | N-Acetylmuramyl-L-alanyl-D-glutaminsäure-alpha-methylamid, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel | |
| JP3138476B2 (ja) | 蠕虫感染を防止及び治療するための化合物 | |
| FR2687156A1 (fr) | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. | |
| CH619470A5 (en) | Process for the preparation of 2-(2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L-seryl-D-iso glutamine and 2-(2-acetamido-2-deoxy-3-O-D-glucopyranosyl)-D-propionyl-L-seryl-D-glu tamic acid | |
| EP0286491B1 (fr) | Dérivés d'aminoquinoléine antimalarique, procédé de préparation et composition pharmaceutique en contenant | |
| CA1250810A (fr) | Hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent | |
| FR2532850A1 (fr) | Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention | |
| EP0139555B1 (fr) | Nouveau peptide de synthèse, son procédé de préparation et médicaments le contenant | |
| FR2621919A1 (fr) | Polypeptides sequentiels dotes d'activite immunologique, procede pour leur preparation, et leur utilisation | |
| WO1979000802A1 (fr) | Nouveaux composes esters de muramyl-peptide et leurs applications dans les compositions pharmaceutiques et reactifs de laboratoire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |